This is the authors' abstract. We don't add key points for this paper.
Our meta-analysis demonstrated the distinct characteristics of IDH1/2-mutated chondrosarcomas in comparison to those without mutations. These mutations could serve as an independent prognostic biomarker to better prognosticate patient outcomes and design appropriate treatment plans.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Vuong et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: